|
|
The Market for Organ and Tissue Transplantation and AlternativesPublished by: BCC Research Published: Oct. 1, 2005 - 343 Pages Table of ContentsINTRODUCTION STUDY GOAL AND OBJECTIVES REASONS FOR DOING THE STUDY CONTRIBUTIONS OF THE STUDY AND FOR WHOM SCOPE AND FORMAT METHODOLOGY INFORMATION SOURCES AUTHOR'S CREDENTIALS RELATED BCC PUBLICATIONS BCC ONLINE SERVICES DISCLAIMER SUMMARY Summary Table: NUMBER OF PROCEDURES AND VALUE OF U.S. ORGAN AND TISSUE TRANSPLANTATION MARKETS, THROUGH 2010 Summary Figure: NUMBER OF PROCEDURES AND VALUE OF U.S. ORGAN AND TISSUE TRANSPLANTATION MARKETS, 2005 AND 2010 OVERVIEW IMPORTANCE OF THE INDUSTRY ORGANS Table 1 U.S. ORGAN TRANSPLANTS: AVERAGE FIRST YEAR COST, NUMBER OF PROCEDURES AND VALUE BY TYPE OF ORGAN TRANSPLANT, THROUGH 2010 KIDNEY LIVER HEART LUNG INTESTINE PANCREAS WAITING LISTS Waiting Lists Grow Faster than Numbers of Transplantations Table 2 PATIENTS ON U.S. WAITING LISTS AT THE END OF THE YEARS BY TYPE OF ORGAN TRANSPLANT, 1999-2003 INTERNATIONAL TRENDS Limited Supply Puts Brakes on Transplantations Table 3 NUMBERS OF DONATED CADAVERS BY REGION, 1997-2003 TISSUES AGING BABY BOOMERS DRIVE THE MARKET Table 4 TISSUE GRAFTING IN THE U.S. BY TISSUE TYPE, THROUGH 2010 (NUMBER OF PROCEDURES) Figure 1 TISSUE GRAFTING IN THE U.S., 2005 AND 2010 (NUMBER OF PROCEDURES) CORNEA BLOOD STEM CELLS BONE ALLOGRAFTS HEART VALVES VASCULAR TISSUE SKIN AND COLLAGEN APPLICATIONS THE TRANSPLANTATION PROCESS PREPARATION SURGERY RECUPERATION MAINTENANCE PRODUCTS IN THE TRANSPLANTATION PROCESS HLA TISSUE TYPING The World Market for HLA Typing Table 5 WORLD MARKET FOR HLA TYPING, THROUGH 2010 ($ MILLIONS) The U.S. Market for HLA Typing Table 6 U.S. MARKET FOR HLA TYPING, THROUGH 2010 ($ MILLIONS) Splitting the Market ORGAN PRESERVATION PRODUCTS ANTIREJECTION DRUGS ANTI-INFECTIVES Table 7 WORLD MARKET FOR ANTI-INFECTIVES USED FOR TRANSPLANT PATIENTS, THROUGH 2010 ($ MILLIONS) POSTTRANSPLANT MONITORING Table 8 WORLD MARKET FOR POSTTRANSPLANT MONITORING, THROUGH 2010 ($ MILLIONS) ALTERNATIVES TO TRANSPLANTATION GOVERNMENT REGULATION AND PATENTS EVOLUTION OF TRANSPLANTATION TISSUE TYPING IMMUNOSUPPRESSION PRESERVATION Improvements in Cold Ischemia Time Table 9 COLD ISCHEMIA TIMES FOR KIDNEYS, 1998-2002 (HOURS) GOVERNMENT REIMBURSEMENT OF TRANSPLANTATION COSTS MECHANICAL ORGANS GENERAL TRENDS SUPPLY MANAGEMENT REDUCING WASTE AND REJECTION INCREASING THE HARVEST Table 10 RECOVERED ORGANS NOT USED BY TYPE, 1998-2003 Table 11 CONSENTED ORGANS NOT RECOVERED BY TYPE, 1998-2003 BETTER HARVESTING Definition of Brain Death Papworth Cocktail Remembering the Ultimate Customer: the Patient on the Waiting List LESS WASTE PRESERVATION Rinse and Preservation Solutions Table 12 MAJOR ORGAN PRESERVATION SOLUTIONS Celsior Collins Solution Custodiol Hypothermosol ViaSpan The Market for Preservation Solutions Table 13 NORTH AMERICAN AND WORLD MARKETS FOR ORGAN PRESERVATION SOLUTIONS (EXCEPT PAPWORK COCKTAIL), THROUGH 2010 Organ Preservation Products in Development Machine Perfusion Bio-Preserve International TransMedics, Inc. Waters Medical Systems NON-HEART-BEATING DONORS TESTING Blood Typing Tissue Typing Panel Reactive Antibodies (PRA) Table 14 TISSUE TYPING TECHNOLOGIES Advances Table 15 SELECTED COMPETITORS IN THE HLA TYPING MARKET Plasmapheresis: Transplantation without Matching Antigens Posttransplant Testing Biotronik Data Sciences Isis Reperfusion Injury FIGHTING REJECTION Table 16 NUMBER OF PATIENTS IN THE U.S. WHO ARE ON WAITING LISTS BECAUSE OF GRAFT FAILURE (FAILURE OF PREVIOUSLY TRANSPLANTED ORGAN), ALL ORGANS, 1995-2003 Table 17 PERCENT OF U.S. PATIENTS ON WAITING LISTS BY ORGAN WHO PREVIOUSLY HAD A TRANSPLANT, 2000-2003 (%) Table 18 U.S. ORGAN RECIPIENTS WHO PREVIOUSLY HAD A TRANSPLANT: ALL ORGANS, 1995-2004 Table 19 NUMBERS OF PEOPLE IN THE U.S. LIVING WITH A FUNCTIONING TRANSPLANT BY TYPE, 1998-2003 IMMUNOSUPPRESSIVE DRUG THERAPY Improvements in Products and Survival Times Table 20 ANTIREJECTION DRUGS APPROVED IN THE U.S., BY CLASS Usual Antirejection Drug Protocols Induction Therapy Table 21 IMMUNOSUPPRESSANT USE FOR INDUCTION, BY ORGAN (%) Maintenance Therapy Table 22 COMMON IMMUNSUPPRESSIVE REGIMENS Table 23 COMMONLY USED INTRAVENOUS IMMUNOSUPPRESIVE DRUGS Table 24 IMMUNOSUPPRESSANT DRUG USE AT TRANSPLANT DISCHARGE, BY ORGAN (%) Table 25 IMMUNOSUPPRESSANT DRUG USE, BY ORGAN, AT END OF FIRST-YEAR POSTTRANSPLANT (%) Rejection Therapy Risks Associated with Immunosuppressive Therapy Annual Cost of Immunosuppressant Drugs Comparison of Annual Cost of Two Immunosuppressant Drug Regimens during the First Year Following Transplantation The Market for Immunosuppressant Drug Therapy Table 26 WORLDWIDE MARKET FOR IMMUNOSUPPRESSION IN SOLID ORGAN TRANSPLANT RECIPIENTS, THROUGH 2010 Table 27 WORLDWIDE SALES OF IMMUNOSUPPRESSIVES BY DRUG CATEGORY, THROUGH 2010 ($ MILLIONS) Table 28 U.S. SALES OF IMMUNOSUPPRESSIVES BY DRUG CATEGORY, THROUGH 2010 ($ MILLIONS) Table 29 WORLDWIDE SALES OF BRAND NAME IMMUNOSUPPRESSANT DRUGS BY COMPANY: 2004-2010 ($ MILLIONS) Table 30 PERCENTAGE OF U.S. MARKET BY PRESCRIPTION VOLUME OF ANTIREJECTION DRUGS, 2004 (%) Products Antibodies Table 31 MARKETED ANTIBODY PRODUCTS FOR TREATMENT OF ORGAN TRANSPLANT REJECTION Monoclonal Antibody Products Campath/MabCampath Antithymocyte Globulin Atgam Thymoglobulin The Market for Antibody Products to Treat Organ Transplant Rejection Table 32 GLOBAL MARKET FOR ANTIBODY PRODUCTS TO TREAT ORGAN TRANSPLANT REJECTION: WORLDWIDE SALES FOR, THROUGH 2010 ($ MILLIONS) Antibodies in Development for Organ Transplant Rejection Table 33 THERAPEUTIC ANTIBODY PRODUCTS IN PHASE II OR LATER DEVELOPMENT FOR THE PREVENTION OF ORGAN TRANSPLANT REJECTION Antiproliferative Agents Azathioprine CellCept Certican Myfortic Calcineurin Inhibitors Concern About Generics Leading Cyclosporine Products Pulminiq: the Newest Entrant to the Market Prograf TOR Inhibitors Immunosuppressive Agents in Development Table 34 IMMUNOSUPPRESSIVE AGENTS IN PHASE II OR LATER DEVELOPMENT Generics HOW THE MEDICARE DRUG DISCOUNT CARD PROGRAM AND THE MEDICARE DRUG BENEFIT WILL AFFECT TRANSPLANT PATIENTS Table 35 MEDICARE IMMUNOSUPPRESIVE DRUG COVERAGE OVERVIEW Table 36 MEDICARE IMMUNOSUPPRESIVE DRUG COVERAGE OVERVIEW (PART II) EFFECT OF PATENT REFORM EFFORTS TO SHORTEN MONOPOLY TIMES ON TRANSPLANTATION DRUG RESEARCH TRANSPLANTATION WITHOUT REJECTION TOLERANCE Antisense Therapy Costimulation Chimerism Abgenix Chimeric Therapies ADDRESSING INFECTION Table 37 COMMON POSTTRANSPLANT INFECTIONS Table 38 COMMON POSTTRANSPLANT DRUGS MONITORING Table 39 WORLD MARKET FOR TRANSPLANT DRUG AND DISEASE-MONITORING AGENTS, THROUGH 2010 ($ MILLIONS) THE EFFICIENCY DIVIDEND TISSUE FINDING MORE SUPPLY EXPANDING TRADITIONAL SOURCES: OBTAINING MORE CADAVERS Spain Sets Donation Standard Table 40 INTERNATIONAL ORGAN DONOR RATES, 2000 (PER MILLION OF POPULATION) The Uniform Anatomical Gift Act Reforms to Boost Donation Presumed Consent Table 41 SELECTED COUNTRIES AND TYPE OF CONSENT First-person Consent Donor Compensation Reimbursement for Donor Organs in the U.K. Tapping New Sources: Expanding Donations to New Nations and Living Donors Shifting Cadaveric Donation Table 42 COUNTRIES WITH KIDNEY TRANSPLANT PROGRAMS Table 43 KIDNEY, LIVER AND HEART TRANSPLANTS BY REGION, 2000 More Competition Splinters the Market Organ Selling Meets Dammed Up Demand Marketing Availability Belgium and Austria Costa Rica Cuba Pakistan South Africa Tissues Effects of Globalization ORGAN DONATION BREAKTHROUGH COLLABORATIVE MAJOR U.S. TRANSPLANT CENTERS Table 44 LEADING U.S. TRANSPLANT PROGRAMS (BY TOTAL NUMBER OF PROCEDURES PERFORMED BETWEEN JANUARY 1, 1988 AND MARCH 1, 2005) Table 45 LEADING U.S. TRANSPLANT PROGRAMS BY NUMBER OF MULTIORGAN TRANSPLANT PROCEDURES PERFORMED BETWEEN JANUARY 1, 1988 AND MARCH 1, 2005 Living Donors Table 46 TRENDS IN U.S. LIVING AND CADAVERIC DONATIONS, 2003-2010 TRENDS IN TRANSPLANTATION OF ALL ORGANS Table 47 U.S. ORGAN TRANSPLANTS, 1998 TO 2004 (NUMBER OF PROCEDURES) Survival Rates Table 48 ONE-YEAR AND FIVE-YEAR PATIENT SURVIVAL RATES, BY ORGAN, FOR PATIENTS RECEIVING TRANSPLANTS BETWEEN 1998 AND 2003 (%) Table 49 ONE-YEAR AND FIVE-YEAR GRAFT SURVIVAL RATES, BY ORGAN FOR TRANSPLANTS PERFORMED BETWEEN 1998 AND 2003 (%) Kidney Exchanges Incompatible Kidney Transplant Program NEW TECHNOLOGIES ORGANS FROM ANIMALS: XENOTRANSPLANTATION ORGAN PRIMORDIA NUCLEAR TRANSFER TO ELIMINATE THE REJECTION GENE Porcine Endogenous Retrovirus Competition Thins Regulatory Issues Political Problems ARTIFICIAL ORGANS REDUCING DEMAND CELLULAR TRANSPLANTS ORGANS KIDNEY TRANSPLANTATION STATISTICS Table 50 NUMBER OF KIDNEY TRANSPLANTATIONS BY REGION, THROUGH 2010 THE MARKET FOR KIDNEY TRANSPLANTATION Table 51 U.S. KIDNEY TRANSPLANT MARKET, THROUGH 2007 ($ MILLIONS) Figure 2 U.S. KIDNEY TRANSPLANT MARKET, 2005 AND 2010 ($ MILLIONS) LEADING U.S. KIDNEY TRANSPLANT PROGRAMS Table 52 TOP FIVE U.S. KIDNEY TRANSPLANT PROGRAMS (BY TOTAL PROCEDURES PERFORMED FROM JANUARY 1, 1988 TO MARCH 1, 2005) TRANSPLANTATION TOO RARE TO BE A SOLUTION WAITING LIST Table 53 WAITING LIST TRENDS FOR KIDNEYS BY SELECTED REGION, THROUGH 2010 Shortage is Worse in Japan CADAVERIC VERSUS LIVING DONATION Table 54 NUMBER OF U.S. KIDNEY TRANSPLANTATIONS FROM LIVING AND CADAVERIC DONORS, THROUGH 2010 CLOSING THE KIDNEY GAP INDICATIONS Table 55 LEADING CAUSES OF KIDNEY FAILURE, 2003 Table 56 LEADING CAUSES OF KIDNEY TRANSPLANTATION, 2004 (%) OLDER RECIPIENTS LESS REJECTION Table 57 GRAFT FAILURE HAZARD RATIO (1993 = 1) IMMUNOSUPPRESSION Table 58 IMMUNOSUPPRESSIVE REGIMENS IN A SAMPLE POPULATION OF 113 KIDNEY TRANSPLANT PATIENTS Drugs Used for Induction Table 59 U.S IMMUNOSUPPRESSION USE FOR INDUCTION IN KIDNEY TRANSPLANTATION, 1998-2003 (%) Drugs Used for Maintenance Prior to Discharge Table 60 U.S. IMMUNOSUPPRESSION DRUG USE FOR MAINTENANCE PRIOR TO DISCHARGE IN KIDNEY TRANSPLANTATION, 1998-2003 (%) Drugs Used for Maintenance Between Discharge and One-year Posttransplant Table 61 U.S. IMMUNOSUPPRESSION DRUG USE FOR MAINTENANCE BETWEEN DISCHARGE AND ONE-YEAR POSTTRANSPLANT IN KIDNEY TRANSPLANTATION, 1998-2002 (%) Drugs Used for Maintenance Between Transplant and One-year Posttransplant Table 62 U.S. IMMUNOSUPPRESSION DRUG USE FOR MAINTENANCE BETWEEN TRANSPLANT AND ONE-YEAR POSTTRANSPLANT IN KIDNEY TRANSPLANTATION, 1998-2002 (%) The Market for Immunosuppressive Therapy for Kidney Transplantation Table 63 U.S. SALES OF IMMUNOSUPPRESSIVES BY DRUG CATEGORY, THROUGH 2010 ($ MILLIONS) Table 64 ESTIMATED U.S. MARKET FOR IMMUNOSUPPRESSIVES FOR KIDNEY TRANSPLANT PATIENTS, THROUGH 2010 ADVANCES IN KIDNEY TRANSPLANTATION ALTERNATIVES Mechanical Medical Animal Cellular PANCREAS TRANSPLANTATION STATISTICS Table 65 GROWTH OF WHOLE PANCREAS TRANSPLANTATION IN THE U.S. AND EUROPE, THROUGH 2010 (NUMBER OF PROCEDURES) THE MARKET FOR PANCREAS TRANSPLANTATION Table 66 U.S. WHOLE PANCREAS TRANSPLANTATION MARKET, THROUGH 2010 ($ MILLIONS) Figure 3 U.S. WHOLE PANCREAS TRANSPLANTATION MARKET, 2005 AND 2010 ($ MILLIONS) WAITING LIST Table 67 U.S. PANCREAS WAITING LIST, THROUGH 2010 LEADING U.S. PANCREAS TRANSPLANT PROGRAMS Table 68 TOP FIVE U.S. KIDNEY TRANSPLANT PROGRAMS (BY TOTAL PROCEDURES PERFORMED FROM JANUARY 1, 1988 TO MARCH 1, 2005) IMMUNOSUPPRESSION Drugs Used for Induction Table 69 U.S. IMMUNOSUPPRESSION DRUG USE FOR INDUCTION IN PANCREAS TRANSPLANTATION, 1998-2003 (%) Drugs Used for Maintenance Prior to Discharge Table 70 U.S. IMMUNOSUPPRESSION DRUG USE FOR MAINTENANCE PRIOR TO DISCHARGE AFTER PANCREAS TRANSPLANTATION, 1998-2003 (%) Drugs Used for Maintenance between Discharge and One-year Posttransplant Table 71 IMMUNOSUPPRESSION DRUG USE IN THE U.S. FOR MAINTENANCE BETWEEN DISCHARGE AND ONE-YEAR POSTTRANSPLANT FOR PANCREAS TRANSPLANTATION, 1998-2002 (%) Drugs Used for Maintenance Between Transplant and One-year Posttransplant Table 72 U.S. IMMUNOSUPPRESSION DRUG USE FOR MAINTENANCE BETWEEN TRANSPLANT AND ONE-YEAR POSTTRANSPLANT IN PANCREAS TRANSPLANTATION, 1998-2002 (%) CONTROVERSY INDICATIONS Table 73 ESTIMATED ANNUAL PER CAPITA PATIENT COSTS FOR DIABETES IN SELECTED COUNTRIES, 2004 ALTERNATIVES Medical Islet Cell Transplantation Table 74 INTERNATIONAL AND U.S. PANCREAS GRAFT SURVIVAL RATES (%) A Breakthrough Juvenile Diabetes Research Foundation Drawbacks Cell Encapsulation AmCyte Biomedical Islet Technology Pig-derived Islet Cells Arbios Systems Bioartificial Pancreas Cerco Medical IMEDD Cultured Stem Cells Protection of Islet Cells Neurochem COSTS LIVER HISTORY TRANSPLANT STATISTICS Table 75 GROWTH OF LIVER TRANSPLANTS BY REGION, THROUGH 2010 (NUMBER OF PROCEDURES) THE MARKET FOR LIVER TRANSPLANTATION Table 76 U.S. LIVER TRANSPLANT MARKET, THROUGH 2010 ($ MILLIONS) Figure 4 U.S. LIVER TRANSPLANT MARKET, 2005 AND 2010 ($ MILLIONS) LEADING U.S. LIVER TRANSPLANT PROGRAMS Table 77 TOP FIVE U.S. LIVER TRANSPLANT PROGRAMS (BY TOTAL PROCEDURES PERFORMED FROM JANUARY 1, 1988 TO MARCH 1, 2005) DONORS Table 78 U.S. TRENDS IN LIVING DONOR LIVER TRANSPLANTS, 2000-2010 WAITING LIST Table 79 REGIONAL GROWTH IN LIVER WAITING LISTS, THROUGH 2010 IMMUNOSUPPRESSION Drugs Used for Induction Table 80 U.S. IMMUNOSUPPRESSION DRUG USE FOR INDUCTION IN LIVER TRANSPLANTATION, 1998-2003 (%) Drugs Used for Maintenance Prior to Discharge Table 81 U.S. IMMUNOSUPPRESSION DRUG USE FOR MAINTENANCE PRIOR TO DISCHARGE IN LIVER TRANSPLANTATION, 1998-2003 (%) Drugs Used for Maintenance between Discharge and One-year Posttransplant Table 82 U.S. IMMUNOSUPPRESSION DRUG USE FOR MAINTENANCE BETWEEN DISCHARGE AND ONE-YEAR POSTTRANSPLANT FOR LIVER TRANSPLANTATION, 1998-2002 (%) Drugs Used for Maintenance Between Transplant and One-year Posttransplant Table 83 U.S. IMMUNOSUPPRESSION DRUG USE FOR MAINTENANCE BETWEEN TRANSPLANT AND ONE-YEAR POSTTRANSPLANT FOR LIVER TRANSPLANTATION, 1998-2002 (%) The Market for Immunosuppressive Drugs in Liver Transplantation Table 84 U.S. MARKET FOR IMMUNOSUPPRESSANT DRUGS FIRST YEAR AFTER LIVER TRANSPLANTATION, THROUGH 2010 ($ MILLIONS) INDICATIONS Causes of Cirrhosis TISSUE TYPING ORGAN RECOVERY REJECTION Table 85 LIVER TRANSPLANT SURVIVAL RATES IN THE U.S. AND EUROPE (%) ALTERNATIVES Medical Artificial Livers Chemical/ Mechanical and /or Bioartificial Livers Table 86 INDICATIONS FOR THE BIOARTIFICIAL LIVER Table 87 BIOARTIFICIAL LIVERS IN DEVELOPMENT Bioartificial Liver Support System ELAD LIVERAID LiveRX 2000 Modular Extracorporeal Liver Support Molecular Adsorption Recycling System Relative Costs HEART TRANSPLANTATION STATISTICS Table 88 DECLINING NUMBERS OF HEART TRANSPLANTATIONS BY REGION, THROUGH 2010 (NUMBER OF PROCEDURES) THE MARKET FOR HEART TRANSPLANTATION Table 89 U.S. HEART TRANSPLANT MARKET, THROUGH 2010 ($ MILLIONS) LEADING U.S. HEART TRANSPLANT PROGRAMS Table 90 TOP FIVE U.S. HEART TRANSPLANT PROGRAMS (BY TOTAL PROCEDURES PERFORMED FROM JANUARY 1, 1988 TO MARCH 1, 2005) FEWER TRANSPLANTS DUE TO TIGHTER SUPPLY Cultural Backlash 1995: A Peak Year SHRINKING WAITING LISTS Table 91 HEART WAITING LIST TRENDS, THROUGH 2010 IMMUNOSUPPRESSION Drugs Used for Induction Table 92 U.S. IMMUNOSUPPRESSION DRUG USE FOR INDUCTION IN HEART TRANSPLANTATION, 1998-2003 (%) Drugs Used for Maintenance Prior to Discharge Table 93 U.S. IMMUNOSUPPRESSION DRUG USE FOR MAINTENANCE PRIOR TO DISCHARGE IN HEART TRANSPLANTATION, 1998-2003 (%) Drugs Used for Maintenance Between Discharge and One-year Posttransplant Table 94 U.S. IMMUNOSUPPRESSION DRUG USE FOR MAINTENANCE BETWEEN DISCHARGE AND ONE-YEAR POSTTRANSPLANT IN HEART TRANSPLANTATION, 1998-2002 (%) Table 95 U.S. IMMUNOSUPPRESSION DRUG USE FOR MAINTENANCE BETWEEN TRANSPLANT AND ONE-YEAR POSTTRANSPLANT IN HEART TRANSPLANTATION, 1998-2002 (%) The Immunosuppressive Drug Market for Heart Transplantation Table 96 U.S. MARKET FOR ANTIREJECTION DRUGS AFTER HEART TRANSPLANTATION, FIRST-YEAR AFTER TRANSPLANT, THROUGH 2010 INDICATIONS Table 97 LEADING CAUSES OF HEART FAILURE, 1999-2003 (%) TISSUE TYPING PRESERVATION ALTERNATIVES Medical Angiogenesis Stimulators Fibroblast Growth Factors Nicotine Gene Therapy Animal Surgical Laser Revascularization Mitral Valve Repair Cardiac Support Devices Mechanical VAD Market VAD Market Table 98 U.S. MARKET FOR VADS, THROUGH 2010 ($ MILLIONS) Table 99 U.S. MARKET FOR VADS USED AS DESTINATION THERAPY, THROUGH 2010 ($ MILLIONS) DeBakey LVAS HeartMate Incor LionHeart Novacor VADs Development in the U.S. Table 100 LEFT VENTRICULAR ASSIST DEVICES IN DEVELOPMENT Arrow International CardiacAssist Jarvik MicroMed Terumo Thoratec Ventracor WorldHeart Product Comparison Medicare Changes Give the VAD Market a Boost The Likelihood of Big Players Entering the Market Total Artificial Hearts AbioCor CardioWest Other Cardiac Assist Devices in Development Regeneration Instead of Replacement Cellular LUNG TRANSPLANTATION STATISTICS Table 101 REGIONAL TRENDS IN LUNG TRANSPLANTATIONS, THROUGH 2010 (NUMBER OF PROCEDURES) THE MARKET FOR LUNG TRANSPLANTATION Table 102 U.S. LUNG TRANSPLANTATION MARKET, THROUGH 2010 ($ MILLIONS) Figure 5 U.S. LUNG TRANSPLANTATION MARKET, 2005 AND 2010 ($ MILLIONS) LEADING U.S. LUNG TRANSPLANT PROGRAMS Table 103 TOP FIVE U.S. LIVER TRANSPLANT PROGRAMS (BY TOTAL PROCEDURES PERFORMED FROM JANUARY 1, 1988 TO MARCH 1, 2005) IMMUNOSUPPRESSION Drugs Used for Induction Table 104 U.S. IMMUNOSUPPRESSION DRUG USE FOR INDUCTION IN LUNG TRANSPLANTATION, 1998-2003 (%) Drugs Used for Maintenance Prior to Discharge Table 105 U.S. IMMUNOSUPPRESSION DRUG USE FOR MAINTENANCE PRIOR TO DISCHARGE IN LUNG TRANSPLANTATION, 1998-2003 (%) Drugs Used for Maintenance between Discharge and One-year Posttransplant Table 106 U.S. IMMUNOSUPPRESSION DRUG USE FOR MAINTENANCE BETWEEN DISCHARGE AND ONE-YEAR POSTTRANSPLANT IN LUNG TRANSPLANTATION, 1998-2002 (%) Drugs Used for Maintenance between Transplant and One-year Posttransplant Table 107 U.S. IMMUNOSUPPRESSION DRUG USE FOR MAINTENANCE BETWEEN TRANSPLANT AND ONE-YEAR POSTTRANSPLANT IN LUNG TRANSPLANTATION, 1998-2002 (%) The Market for Immunosuppressive Drugs Used in Lung Transplantation Table 108 U.S. MARKET FOR ANTIREJECTION DRUGS AFTER LUNG TRANSPLANTATION, FIRST YEAR AFTER TRANSPLANT, THROUGH 2010 ($ MILLIONS) DONATION Table 109 RECOVERED LUNGS NOT USED IN THE U.S., 1998-2003 Hormonal Resuscitation WAITING LISTS Table 110 LUNG WAITING LIST TRENDS, THROUGH 2010 REJECTION Table 111 INTERNATIONAL AND U.S. LUNG TRANSPLANT AND GRAFT SURVIVAL RATES* (%) INDICATIONS Table 112 LEADING CAUSES OF CHRONIC LUNG FAILURE, 1998-2002 (%) PRESERVATION Celsior Prolactin ALTERNATIVES Medical Surgical Cellular HEART-LUNG TRANSPLANTATION STATISTICS Table 113 TRENDS IN HEART-LUNG TRANSPLANTATION BY REGION, THROUGH 2010 (NUMBER OF PROCEDURES) THE MARKET FOR HEART-LUNG TRANSPLANTATION Table 114 U.S. HEART-LUNG TRANSPLANT MARKET, THROUGH 2010 ($ MILLIONS) Figure 6 U.S. HEART-LUNG TRANSPLANT MARKET, 2005 AND 2010 ($ MILLIONS) THE LEADING U.S. HEART-LUNG TRANSPLANT PROGRAMS Table 115 TOP FIVE U.S. LIVER TRANSPLANT PROGRAMS (BY TOTAL PROCEDURES PERFORMED FROM JANUARY 1, 1988 TO MARCH 1, 2005) WAITING LIST Table 116 HEART-LUNG WAITING LIST TRENDS, THROUGH 2010 SURVIVAL RATES Table 117 INTERNATIONAL HEART AND HEART-LUNG TRANSPLANT PATIENT SURVIVAL RATES (%) IMMUNOSUPPRESSION Drugs Used for Induction Table 118 U.S. IMMUNOSUPPRESSION DRUG USE FOR INDUCTION IN HEART-LUNG TRANSPLANTATION, 1998-2003 (%) Drugs Used for Maintenance Prior to Discharge Table 119 U.S IMMUNOSUPPRESSION DRUG USE FOR MAINTENANCE PRIOR TO DISCHARGE IN HEART-LUNG TRANSPLANTATION, 1998-2003 (%) Drugs Used for Maintenance Between Discharge and One-year Posttransplant Table 120 U.S. IMMUNOSUPPRESSION DRUG USE FOR MAINTENANCE BETWEEN DISCHARGE AND ONE-YEAR POSTTRANSPLANT IN HEART-LUNG TRANSPLANTATION, 1998-2002 (%) Table 121 U.S. IMMUNOSUPPRESSION DRUG USE FOR MAINTENANCE BETWEEN TRANSPLANT AND ONE-YEAR POSTTRANSPLANT IN HEART-LUNG TRANSPLANTATION, 1998-2002 (%) INTESTINE HISTORY TRANSPLANTATION STATISTICS Table 122 INTERNATIONAL AND U.S. INTESTINE TRANSPLANT SURVIVAL RATES (%) Table 123 U.S. SMALL BOWEL TRANSPLANTATION TRENDS, THROUGH 2010 THE MARKET FOR INTESTINE TRANSPLANTATION Table 124 U.S. SMALL BOWEL TRANSPLANTATION MARKET, THROUGH 2010 ($ MILLIONS) Figure 7 U.S. SMALL BOWEL TRANSPLANTATION MARKET, 2005 AND 2010 ($ MILLIONS) LEADING U.S. INTESTINE TRANSPLANT PROGRAMS Table 125 TOP FIVE U.S. LIVER TRANSPLANT PROGRAMS (BY TOTAL PROCEDURES PERFORMED FROM JANUARY 1, 1988 TO MARCH 1, 2005) COUNTRIES WITH SMALL BOWEL TRANSPLANT PROGRAMS Table 126 COUNTRIES WITH SMALL BOWEL TRANSPLANT PROGRAMS LACK OF SURGICAL SUCCESS TRANSPLANT TYPES INDICATIONS Table 127 LEADING INIDICATIONS FOR INTESTINE TRANSPLANT: ADULT PATIENTS, 2003 (%) Table 128 LEADING INDICATIONS FOR INTESTINE TRANSPLANT: PEDIATRIC PATIENTS, 2003 (%) IMMUNOSUPPRESSION Drugs Used for Induction Table 129 U.S IMMUNOSUPPRESSION DRUG USE FOR INDUCTION IN INTESTINE TRANSPLANTATION, 1998-2003 (%) Drugs Used for Maintenance Prior to Discharge Table 130 U.S. IMMUNOSUPPRESSION DRUG USE FOR MAINTENANCE PRIOR TO DISCHARGE IN INTESTINE TRANSPLANTATION, 1998-2003 (%) Drugs Used for Maintenance Between Discharge and One-year Posttransplant Table 131 U.S. IMMUNOSUPPRESSION DRUG USE FOR MAINTENANCE BETWEEN DISCHARGE AND ONE-YEAR POSTTRANSPLANT IN INTESTINE TRANSPLANTATION, 1998-2002 (%) Drugs Used for Maintenance Between Transplant and One Year Posttransplant Table 132 U.S. IMMUNOSUPPRESSION DRUG USE FOR MAINTENANCE BETWEEN TRANSPLANT AND ONE YEAR POSTTRANSPLANT IN INTESTINE TRANSPLANTATION, 1998-2002 (%) The Market for Immunosuppressive Drugs Used in Intestine Transplantation Table 133 U.S. MARKET FOR ANTIREJECTION DRUGS AFTER SMALL BOWEL TRANSPLANTATION, FIRST YEAR AFTER TRANSPLANTATION, THROUGH 2010 ($ MILLIONS) INFECTION PROPHYLAXIS ALTERNATIVES Medical Mechanical Cellular TISSUES OVERVIEW MANDATORY REFERRALS PUBLIC CYNICISM DONOR COMPENSATION CORNEA Table 134 CORNEAL TRANSPLANTS IN SELECTED COUNTRIES, 1999-2003 Table 135 CORNEAL TRANSPLANTS AND U.S. MARKET, THROUGH 2010 Figure 8 U.S. CORNEAL TRANSPLANT MARKET, 2005 AND 2010 ($ MILLIONS) Donors Table 136 NUMBER OF U.S. CORNEA DONORS, 1999-2004 Waiting Lists U.S. Other Countries Indications Tissue Testing Preservation Cryopreservation Immunosuppression Alternatives Surgical Artificial Corneas RETINAL DEGENERATION Cellular Transplants Gene Therapy Electronic Implants BLOOD STEM CELLS HISTORY First Successful Transplant Donor Registry Established Cord Blood Cord Blood Banking PROCEDURE VOLUMES Table 137 ESTIMATED U.S. BONE MARROW TRANSPLANTS, 1998-2004 Table 138 PROJECTED U.S. BONE MARROW TRANSPLANT PROCEDURES, THROUGH 2010 Autologous Passes Allogeneic Less Bone Marrow DONORS Table 139 BMDW MEMBER HOME COUNTRIES Potential for HLA Testing Table 140 NUMBERS OF BONE MARROW DONORS PER 10,000 INHABITANTS WAITING LISTS REJECTION Table 141 U.S. MARKET FOR IMMUNOSUPPRESSIVE DRUG THERAPY FOLLOWING BONE MARROW TRANSPLANTATION, THROUGH 2010 ($ MILLIONS) Table 142 U.S. MARKET FOR IMMUNOSUPPRESSIVE DRUG THERAPY FOLLOWING BLOOD STEM CELL TRANSPLANTATION, THROUGH 2010 ($ MILLIONS) INDICATIONS IMMUNOSUPPRESSION Abgenix University of Pennsylvania ALTERNATIVES Expanding Cord Blood Replicell BONE HISTORY PROCEDURES Table 143 U.S. BONE GRAFT PROCEDURE VOLUMES BY APPLICATION, THROUGH 2010 Table 144 U.S. BONE GRAFT PROCEDURE VOLUMES BY TYPE OF GRAFT, THROUGH 2010 MARKET TOTALS Table 145 U.S. AND WORLDWIDE ORTHOPEDIC IMPLANT MARKET GROWTH, THROUGH 2010 ($ BILLIONS) Figure 9 U.S. AND WORLDWIDE IMPLANT MARKET GROWTH, 2005 AND 2010 ($ BILLIONS) AUTOGRAFTS ALLOGRAFTS Risks Associated with Allografts Products Base Tissue Demineralized Bone Matrix Products Machined Implants The Market for Allografted Tissue Table 146 U.S. AND WORLD VALUES OF THE BONE ALLOGRAFT MARKET, THROUGH 2010 ($ MILLIONS) Figure 10 VALUE OF THE U.S. AND WORLD BONE ALLOGRAFT MARKET, 2005 AND 2010 ($ MILLIONS) Table 147 U.S. SALES OF BONE ALLOGRAFTS BY TYPE, THROUGH 2010 ($ MILLIONS) Figure 11 U.S. SALES OF BONE ALLOGRAFTS BY TYPE, 2005 AND 2010 ($ MILLIONS) BONE GRAFT SUBSTITUTES Table 148 COMPARISON OF BONE GRAFT MATERIALS Table 149 SUBSTITUTE BONE GRAFT TYPES FACTOR-BASED BONE GRAFT SUBSTITUTES Bone Morphogenic Proteins (BMPs) InductOs INFUSE® Bone Graft Ne-Osteo OP-1 Implant® Skelite® THE MARKET FOR BONE GRAFT PRODUCTS Table 150 WORLDWIDE MARKET FOR BONE GRAFT PRODUCTS, THROUGH 2010 ($ MILLIONS) INDICATIONS TISSUE TESTING Preventing Infection PRESERVATION COMPETITION ALTERNATIVES Animal Bone Grafts Medical Synthetic Materials Orthovita Spine Wave Meniscus Allografts Collagen Meniscus Implant REPLACEMENT HEART VALVES, ARTERIES AND OTHER VESSELS HISTORY INDICATIONS PROCEDURES Table 151 NUMBER OF U.S. HEART VALVE TRANSPLANTS AND BYPASS OPERATIONS, 1998-2004 DONORS Valves from Morgues HEART VALVE ALLOGRAFT MARKET Table 152 U.S. AND WORLD HEART VALVE TRANSPLANT MARKET, THROUGH 2010 ($ MILLIONS) TISSUE TESTING PRESERVATION AND PROCESSING Synthetics Xenografts Defects and Regulation ADVANCES ALTERNATIVES Animal Stentless Valves Calcification Surgical Coronary Bypass Grafts Medical Heart Valve and Vascular Disease Mechanical/Synthetic Improving Blood Flow Better Maintenance Tissue Valves Gain Popularity Major Competitors VASCULAR GRAFTS Waiting List Indications Advances Products Tissue Engineering of Vascular Grafts Alternatives Gene Therapy SKIN Table 153 U.S. MARKET FOR HUMAN SKIN-BASED PRODUCTS, THROUGH 2010 HISTORY INDICATIONS Burns Wounds Venous Ulcers Table 154 ESTIMATED INCIDENCE OF VENOUS ULCERS IN THE U.S. OVER-64 POPULATION, THROUGH 2010 Diabetic Ulcers Table 155 ESTIMATED U.S. INCIDENCE OF DIABETIC FOOT ULCERS, THROUGH 2010 Pressure Ulcers Urinary Incontinence and Other Uses Table 156 U.S. TENDON, CARTILAGE AND MUSCLE GRAFTS, 1998-2004 REJECTION TISSUE TESTING PRESERVATION Alternatives Animal-based Products Biobrane OaSIS Medical Artificial Skin/Skin Replacement Products AlloDerm Apligraf Cymetra Dermagraft Epicel Integra Products OrCel TransCyte Manufacturers of Artificial Skin and Skin Replacement Products Table 157 MANUFACTURERS OF ARTIFICIAL SKIN AND SKIN REPLACMENT PRODUCTS The Market for Artificial Skin and Skin Replacment Products Table 158 ESTIMATED WORLDWIDE MARKET FOR ARTIFICIAL SKIN AND SKIN REPLACEMENT PRODUCTS, THROUGH 2010 ($ MILLIONS) Table 159 ESTIMATED U.S. MARKET FOR ARTIFICIAL SKIN AND SKIN REPLACEMENT PRODUCTS, THROUGH 2010 ($ MILLIONS) Products in Development Other Research REGULATION CELLULAR TRANSPLANTATION HISTORY FOUR TYPES OF CELLS OFFER POTENTIAL NUMBERS DONORS REJECTION INDICATIONS PATENTS New Rule Requires Demonstrating Specific and Substantial Utility ALTERNATIVES COMPANY PROFILES ABIOMED, INC. BUSINESS OVERVIEW ABIOMED DEVELOPS, MANUFACTURES AND MARKETS MEDICAL PRODUCTS TO SUPPORT, REPLACE OR ALLOW RECOVERY OF THE PUMPING FUNCTION OF A FAILING HEART. FINANCIAL INFORMATION PRODUCTS CORPORATE STRATEGY ARBIOS SYSTEMS, INC. BUSINESS OVERVIEW FINANCIAL INFORMATION PRODUCTS CORPORATE STRATEGY ARROW INTERNATIONAL, INC. BUSINESS OVERVIEW FINANCIAL INFORMATION PRODUCTS ASTELLAS PHARMA INC. BUSINESS OVERVIEW FINANCIAL INFORMATION PRODUCTS CHIRON CORP. BUSINESS OVERVIEW FINANCIAL INFORMATION PRODUCTS CRYOLIFE, INC. BUSINESS OVERVIEW FINANCIAL INFORMATION PRODUCTS AND SERVICES EXACTECH, INC. BUSINESS OVERVIEW FINANCIAL INFORMATION PRODUCTS CORPORATE STRATEGY GAMBRO AB BUSINESS OVERVIEW FINANICAL INFORMATION PRODUCTS CORPORATE STRATEGY GENZYME CORP. WEB SITE: WWW.GENZYME.COM BUSINESS OVERVIEW FINANCIAL INFORMATION PRODUCTS CORPORATE STRATEGY HEMOCLEANSE, INC. BUSINESS OVERVIEW PRODUCTS CORPORATE STRATEGY LIFECELL CORP. BUSINESS OVERVIEW FINANCIAL INFORMATION PRODUCTS CORPORATE STRATEGY MEDTRONIC, INC. BUSINESS OVERVIEW FINANCIAL INFORMATION PRODUCTS CORPORATE STRATEGY MILLENIUM BIOLOGIX, INC. BUSINESS OVERVIEW PRODUCTS CORPORATE STRATEGY NOVARTIS AG BUSINESS OVERVIEW FINANCIAL INFORMATION PRODUCTS ORGANOGENESIS, INC. BUSINESS OVERVIEW PRODUCTS CORPORATE STRATEGY ORTEC INTERNATIONAL, INC. BUSINESS OVERVIEW PRODUCTS CORPORATE STRATEGY PROTEIN DESIGN LABS BUSINESS OVERVIEW FINANCIAL INFORMATION PRODUCTS CORPORATE STRATEGY SYNCARDIA SYSTEMS, INC. BUSINESS OVERVIEW PRODUCTS CORPORATE STRATEGY THORATEC CORP. BUSINESS OVERVIEW FINANCIAL INFORMATION PRODUCTS CORPORATE STRATEGY WORLDHEART CORP. BUSINESS OVERVIEW FINANCIAL INFORMATION PRODUCTS CORPORATE STRATEGY WYETH BUSINESS OVERVIEW FINANCIAL INFORMATION PRODUCTS AbstractOrgan failure and tissue loss account for half the medical spending in the U.S. In theory, transplantation is the last therapeutic option available to people in the final stage of an organ or tissue failure. In reality, the supply of organs or tissues is so limited that for the vast majority of people, transplantation is not an option. At the same time, transplantation outcomes are under renewed scrutiny as insurers try to control healthcare costs.The organ transplantation business currently faces some of its toughest challenges and hurdles. At the same time, exciting fields of research offer hope for overcoming those challenges. Hence, tremendous opportunities exist to meet growing market demand and to cut costs. But, at the same time, competitors have great opportunities to provide equivalent outcomes at reduced cost. This report is a valuable tool for anyone assessing the organ and tissue transplantation market and attempting to devise a strategy to address it successfully. This BCC study provides an in-depth analysis and forecast of the organ and tissue transplantation markets. The focus is on products and procedures used or under development including techniques, therapies, drugs and diagnostics. SCOPE OF STUDY The report contains:
Information for this report was derived from a variety of sources, including that provided by product managers, marketing strategists, research executives and others at leading companies in the tissue transplantation market and at companies poised to enter the market. Others consulted include transplant surgeons, directors of transplant programs or tissue typing laboratories, and other medical professionals who participate in processes involved with transplantation, or who compete against it. Other data came from company annual reports and 10Ks, journal articles, prospectus assessments, government resources and from healthcare institutions. INFORMATION SOURCES Information for this report was obtained from primary interviews with companies, industry analysts, healthcare personnel, Center for Medicare and Medicaid Services (CMS) and other government agencies, literature searches, annual reports, 10Ks and product literature. Get Full Details About This Report >> |
|
|||
|
About MarketResearch.com
|
||||